Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program
- Agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1b
- Deal is a major step forward for Fibrocor’s plans to develop FIB918, its monoclonal antibody for Alport Syndrome, a rare disease with very limited treatment options
- Fibrocor and MSRD intend to start Phase 1 clinical trials of its monoclonal antibody in 2025
Toronto, Canada – 5 March 2024 – Fibrocor Therapeutics Inc. (‘Fibrocor’ or ‘the Company’), a privately held developer of novel therapeutics to treat fibrosis, today announces that it has entered into a research and development collaboration with the McQuade Center for Strategic Research and Development, LLC (MSRD) to advance its Alport Syndrome program.
